Medicus Pharma to spin off SkinJect via business combination with SPAC
Medicus Pharma announced a non-binding LOI with a SPAC to combine its subsidiary SkinJect, valuing the entity at $135M, alongside concurrent financing to fund a Gorlin Syndrome study.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed